The Sybil prophecy: Searching for predictors of response to bevacizumab in glioblastoma

被引：0
|
作者：
Offi, Martina [1 ,2 ]
Gabriele, Lucia [1 ,3 ]
Romagnoli, Giulia [3 ]
Lauretti, Liverana [2 ]
Pallini, Roberto [1 ,2 ]
D'Alessandris, Quintino Giorgio [1 ,2 ]
机构：
[1] Catholic Univ, Sch Med, Dept Neurosci, Largo A Gemelli 8, I-00168 Rome, Italy
[2] Fdn Policlin Gemelli IRCCS, Dept Neurosurg, Largo A Gemelli 8, I-00168 Rome, Italy
[3] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy
来源：
NEURO-ONCOLOGY | 2024年 / 26卷 / 08期
关键词：
D O I：
10.1093/neuonc/noae088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1538 / 1539
页数：2
相关论文
共 50 条
  • [21] The Role of Bevacizumab in Glioblastoma
    Nabors, L. Burt
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (09): : 1201 - 1202
  • [22] Bevacizumab in recurrent glioblastoma
    Martinez, Nina L.
    Glass, Jon
    Shi, Wenyin
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S162 - S163
  • [23] IPILIMUMAB AND BEVACIZUMAB IN GLIOBLASTOMA
    Mulholland, Paul
    Shaw, Heather
    NEURO-ONCOLOGY, 2014, 16
  • [24] Radiomic Response Assessment for Recurrent Glioblastoma Treated with Bevacizumab in the BRAIN Trial
    Grossmann, P.
    Narayan, V.
    Huang, R.
    Aerts, H.
    MEDICAL PHYSICS, 2016, 43 (06) : 3751 - 3752
  • [25] ANGIOTENSINOGEN GENE SILENCING PREDICTS BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS
    Urup, Thomas
    Gillberg, Linn
    Michaelsen, Signe
    Christensen, Ib
    Broholm, Helle
    Lassen, Ulrik
    Groenbaek, Kirsten
    Poulsen, Hans
    NEURO-ONCOLOGY, 2018, 20 : 162 - 163
  • [26] Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
    Vaios, Eugene J.
    Winter, Sebastian F.
    Muzikansky, Alona
    Nahed, Brian V.
    Dietrich, Jorg
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [27] Response assessment of bevacizumab for glioblastoma: Comparison between PET and pathological studies
    Miyake, Keisuke
    Ogawa, Daisuke
    Okada, Masaki
    Hatakeyama, Tetsuhiro
    Haba, Reiji
    Tamiya, Takashi
    BRAIN PATHOLOGY, 2019, 29 : 112 - 112
  • [28] Predicting Glioblastoma Response to Bevacizumab Through MRI Biomarkers of the Tumor Microenvironment
    Andreas Stadlbauer
    Karl Roessler
    Max Zimmermann
    Michael Buchfelder
    Andrea Kleindienst
    Arnd Doerfler
    Gertraud Heinz
    Stefan Oberndorfer
    Molecular Imaging and Biology, 2019, 21 : 747 - 757
  • [29] A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma
    A. F. Cardona
    L. Rojas
    B. Wills
    A. Ruiz-Patiño
    L. Abril
    F. Hakim
    E. Jiménez
    N. Useche
    S. Bermúdez
    J. A. Mejía
    J. F. Ramón
    H. Carranza
    C. Vargas
    J. Otero
    P. Archila
    J. Rodríguez
    J. Rodríguez
    J. Behaine
    D. González
    J. Jacobo
    H. Cifuentes
    O. Feo
    P. Penagos
    D. Pineda
    L. Ricaurte
    L. E. Pino
    C. Vargas
    J. C. Marquez
    M. I. Mantilla
    L. D. Ortiz
    C. Balaña
    R. Rosell
    Z. L. Zatarain-Barrón
    O. Arrieta
    Clinical and Translational Oncology, 2019, 21 : 1364 - 1373
  • [30] Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab
    Wu, J.
    Gilbert, M. R.
    De Groot, J. F.
    Yung, W. A.
    Puduvalli, V. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345